Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101
San Diego, California--(Newsfile Corp. - September 17, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical...
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


